BACKGROUND: About 15% of the population have @entity364 of the feet ( @entity14654 or @entity14654 ). Whilst there are many clinical presentations of @entity14654 the most common are between the toes (interdigital) and on the soles, heels and sides of the foot (plantar) which is known as moccasin foot. Once acquired the @entity281 can spread to other sites including the nails, which can be a source of reinfection. Oral therapy is usually used for chronic conditions or when topical treatment has failed. OBJECTIVES: To assess the effects and costs of oral treatments for @entity364 of the skin of the foot ( @entity14654 ). SEARCH STRATEGY: Randomised controlled trials were identified from MEDLINE, EMBASE and CINAHL from the beginning of these databases to January 2000. We also searched the Cochrane Controlled trials Register (Cochrane Library issue 1, 2000) the Science Citation Index, BIOSIS, @entity17698 -Health, Health star and Economic databases. Bibliographies were searched, podiatry journals hand searched and the pharmaceutical industry and schools of podiatry contacted. SELECTION CRITERIA: Randomised controlled trials including @entity1 who have a clinically diagnosed @entity14654 , confirmed by microscopy and growth of dermatophytes in culture. DATA COLLECTION AND ANALYSIS: Study selection was done by two independent reviewers. Methodological quality assessment and data collection was also assessed by two independent reviewers. MAIN RESULTS: Twelve trials, involving 700 @entity1 , were included. The two trials comparing @entity8974 and @entity3101 produced a pooled risk difference of 52% (95% confidence intervals 33% to 71%) in favour of @entity8974 's ability to cure @entity281 . No significant difference was detected between @entity8974 and @entity2059 ; @entity2380 and either @entity2059 and @entity3102 ; or between @entity3101 and @entity3102 , although the trials were generally small. Two trials showed that @entity8974 and @entity2059 were effective compared with placebo. Adverse effects were reported for all drugs, with gastrointestinal effects most commonly reported. REVIEWERS' CONCLUSIONS: The evidence suggests that @entity8974 is more effective than @entity3101 and that @entity8974 and @entity2059 are more effective than no treatment.

[Systematic treatment of XXXX --evidence for treatment? A result of a Cochrane review].

@entity1 :: ('9606', 'Species') :: ['participants'] @entity14654 :: ('MESH:D014008', 'Disease') :: ["athlete's foot", 'tinea pedis'] @entity8974 :: ('MESH:C041359', 'Chemical') :: ['terbinafine'] @entity3101 :: ('MESH:D006118', 'Chemical') :: ['griseofulvin'] @entity2380 :: ('MESH:D015725', 'Chemical') :: ['fluconazole'] @entity3102 :: ('MESH:D007654', 'Chemical') :: ['ketoconazole'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity364 :: ('MESH:D009181', 'Disease') :: ['fungal infections'] @entity17698 :: ('56654', 'Gene') :: ['CAB'] @entity2059 :: ('MESH:D017964', 'Chemical') :: ['itraconazole']
@entity14654 :: (MESH:D014008,Disease) :: ['tinea pedis']
